Ontology highlight
ABSTRACT: Background
In the Strategic Timing of Antiretroviral Treatment (START) study, immediate combination antiretroviral therapy (cART) initiation reduced cancer risk by 64%. We hypothesized that risk reduction was higher for infection-related cancer and determined by differences in CD4 cell counts and human immunodeficiency virus (HIV) RNA between the study arms.Methods
Incident malignancies in START were categorized into infection-related and infection-unrelated cancer. We used Cox models to assess factors associated with both cancer categories. We used sequential adjustment for baseline covariates, cancer risk factors, and HIV-specific variables to investigate potential mediators of cancer risk reduction with immediate cART.Results
There were 14 cancers among person
SUBMITTER: Borges AH
PROVIDER: S-EPMC5146718 | biostudies-literature | 2016 Dec
REPOSITORIES: biostudies-literature